arsenic trioxide; As2O3 (Trisenox)
Jump to navigation
Jump to search
Introduction
Tradename: Trisenox. (As2O3)
Indications
- treatment of acute promyelocytic leukemia
- treatment of acute myelomonocytic leukemia[3][4]
- treatment of myelodysplastic syndrome[2]
Dosage
- injectable arsenic
Pharmacokinetics
- within 24 hours, arsenic is distributed to all body tissues
- the major route of excretion is through the kidneys
- arsenic crosses the placenta
Monitor
Adverse effects
More general terms
Additional terms
References
- ↑ Prescriber's Letter 8(2):supplement 2001
- ↑ 2.0 2.1 Deprecated Reference
- ↑ 3.0 3.1 Powell BL, Moser B, Stock W, Gallagher RE et al Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010 Nov 11;116(19):3751-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20705755
- ↑ 4.0 4.1 Lo-Coco F, Avvisati G, Vignetti M et al Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23841729
- ↑ 5.0 5.1 5.2 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015